TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma.
The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)‘ (abstract number 9503) was presented at the 2021 ASCO Annual Meeting.
- Could you tell us a little about relatlimab, and the rationale for using it in combination with nivolumab in the treatment of advanced melanoma? (0:22)
- What were the aim, design and clinical endpoints of the RELATIVITY-047 study? (1:21)
- How well were survival and safety endpoints met? (2:38)
- Which subgroups were most likely to benefit from this combined therapy? (3:39)
- How do these findings compare with those of the Checkmate-067 study? (4:06)
- What were the conclusions from the study and how do the findings influence the future treatment landscape? (4:50)
Disclosures: Advisory Board (Personal): Bristol Myers-Squibb, Novartis, EMD Serono, Array BioPharma, Merck, Sanofi, Regeneron, Genentech, Odonate Therapeutics; Consultant/ Other (Personal): Macrogenics; Local PI (No financial interest, Institutional): Regeneron, Merck; Coordinating PI (No financial interest, Institutional): Bristol-Myers Squibb.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Dermatological Cancers
Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
The STARBOARD trial will investigate encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the mechanisms of encorafenib, binimetinib and pembrolizumab, as well as details on the STARBOARD trial. The presentation entitled […]
Ryan Sullivan, AACR 2023: Current therapeutic options for BRAF V600 mutated melanoma
Multiple therapies that have been approved for the treatment of BRAF V600 mutated melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the current treatment paradigm and its limitations. Ryan Sullivan presented an abstract entitled ‘Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + […]
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!